RVX297 manufacturers
- RVX-297
-
- $41.00
-
2026-07-13
- CAS:1044871-04-6
- Purity: 99.62%
- Supply Ability: 10g
|
| Product Name: | RVX297 | | Synonyms: | RVX297;4(3H)-Quinazolinone, 2-[3,5-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5,7-dimethoxy-;2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;autoimmunity,RVX 297,proinflammatory,Epigenetic Reader Domain,RVX-297,immune,inhibit,mediator,inflammatory,Inhibitor,selectivity,acute,cell,arthritis;2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(1H)-one;2-{3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,7-dimethoxy-1,4-dihydroquinazolin-4-one;2-(3,5-Dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one , RVX-297;RVX-297, 10 mM in DMSO | | CAS: | 1044871-04-6 | | MF: | C24H29N3O4 | | MW: | 423.5 | | EINECS: | | | Product Categories: | | | Mol File: | 1044871-04-6.mol |  |
| | RVX297 Chemical Properties |
| Boiling point | 612.6±65.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (118.06 mM; Need ultrasonic) | | pka | 9.54±0.20(Predicted) | | form | Solid | | color | White to light brown |
| | RVX297 Usage And Synthesis |
| Uses | RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models[1][2]. | | in vivo | RVX-297 (25-75 mg/kg; p.o.; per day for 6 day) inhibits progression of pathology in the rat collagen-induced arthritis model[1].
RVX-297 (75-150 mg/kg) inhibits progression of pathology in the mouse collagen-induced arthritis model[1].
RVX-297 suppresses cytokine production in LPS-treated mice[1]. | Animal Model: | Female Lewis rats are 6-8 weeks old, approximately 150 g (rat collagen-induced arthritis)[1] | | Dosage: | 25, 50, and 75 mg/kg | | Administration: | P.o.; per day for 6 days | | Result: | Prevented swelling and inflammation of the ankle and knee joints.
|
| | IC 50 | BRD2 (BD1): 3.76 μM (IC50); BRD2 (BD2): 0.08 μM (IC50); BRD3 (BD1): 2.34 μM (IC50); BRD3 (BD2): 0.05 μM (IC50); BRD4 (BD1): 1.16 μM (IC50); BRD4 (BD2): 0.02 μM (IC50); BRDT (BD1): 2.69 μM (IC50) | | References | [1] Jahagirdar R, et al. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease. Mol Pharmacol. 2017;92(6):694-706. DOI:10.1124/mol.117.110379
[2] Kharenko OA, et al. RVX-297- a novel BD2 selective inhibitor of BET bromodomains. Biochem Biophys Res Commun. 2016;477(1):62-67. DOI:10.1016/j.bbrc.2016.06.021 |
| | RVX297 Preparation Products And Raw materials |
|